Obesity and CHD
This article was originally published in The Tan Sheet
Executive Summary
Even without additional risk factors, obesity in young adulthood and middle-age carries an increased risk of hospitalization or death from coronary heart disease, cardiovascular disease or diabetes in older age compared to normal weight individuals, a study in the Jan. 11 Journal of the American Medical Association finds. For instance, the risk of death from CHD was 43% higher for obese individuals in the low-risk group compared to normal weight individuals at the same risk level, according to Lijing Yan, PhD, Feinberg School of Medicine, Northwestern University, et al. The findings, which were gleaned from a multivariable analysis of 17,643 participants in the Chicago Heart Association Detection Project, have "significant public health implications," the authors conclude. GlaxoSmithKline's switch application for the anti-obesity drug Xenical (orlistat) will be reviewed by two FDA advisory committees Jan. 23 (1"The Tan Sheet" Jan. 2, 2006, p. 3)...
You may also be interested in...
Xenical Short-Term Switch Odds Slimmer Than Long-Term – Experts
Xenical's long-term prospect for switch appears promising, but its chances of being recommended for OTC sale by an upcoming advisory panel are slim, some switch experts say
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.